ITF2357 50mg 50mg | Purity Not Available
Adooq Bioscience
ITF2357 (Givinostat) is a HDACs inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities.
More Information Supplier PageSearch Results
ITF2357 5mg 5mg | Purity Not Available
Adooq Bioscience
ITF2357 (Givinostat) is a HDACs inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities.
More Information Supplier PageITF2357 (Givinostat) 10mM * 1mL in DMSO 10mM * 1mL in DMSO | Purity Not Available
Adooq Bioscience
ITF2357 (Givinostat) is a HDACs inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities.
More Information Supplier PageITF2357 100mg 100mg | Purity Not Available
Adooq Bioscience
ITF2357 (Givinostat) is a HDACs inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities.
More Information Supplier PageIvermectin 2g 2000mg | Purity Not Available
Adooq Bioscience
Ivermectin 500mg 500mg | Purity Not Available
Adooq Bioscience
JNJ-26481585 10mM * 1mL in DMSO 10mM * 1mL in DMSO | Purity Not Available
Adooq Bioscience
JNJ-26481585 is a pan-HDAC inhibitor with marked potency toward HDAC1 (IC(50), 0.16 nmol/L).
More Information Supplier PageJNJ-26481585 100mg 100mg | Purity Not Available
Adooq Bioscience
JNJ-26481585 is a pan-HDAC inhibitor with marked potency toward HDAC1 (IC(50), 0.16 nmol/L).
More Information Supplier PageJNJ-26481585 10mg 10mg | Purity Not Available
Adooq Bioscience
JNJ-26481585 is a pan-HDAC inhibitor with marked potency toward HDAC1 (IC(50), 0.16 nmol/L).
More Information Supplier PageJNJ 26854165 50mg 50mg | Purity Not Available
Adooq Bioscience
JNJ-26854165 is one of p53-activating agents and synergizes with AraC or doxorubicin to induce p53-mediated apoptosis and may provide a novel therapeutic approach for the treatment of acute leukemias.
More Information Supplier Page